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1. Introduction 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients 
with diabetes mellitus (DM). DM is considered as a coronary artery disease equivalent for 
future risk of vascular events. There are 3 different classes of platelet-inhibiting drugs: 
cyclooxygenase-1 (COX-1) inhibitors (aspirin), ADP P2Y12 receptor antagonists 
(thienopyridines), and platelet glycoprotein (GP) IIb/IIIa inhibitors, and these platelet 
inhibitors are mostly used for the prevention and treatment of atherothrombotic disorders.  
Aspirin inhibits the COX-1 enzyme and therefore blocks platelet thromboxane A2 synthesis. 
In 2007, the American Diabetes Association (ADA) and the American Heart Association 
(AHA) jointly recommended primary prevention strategy in those with diabetes, and that 
was modified by The U.S. Preventive Services Task Force recently; they did not differentiate 
their recommendations based on the presence or absence of diabetes. ADA recommends the 
use of low-dose aspirin (75–162 mg/day) for secondary prevention of cerebrovascular and 
cardiovascular events in all diabetic patients. In this chapter we discuss the cardiovascular 
risk in diabetes, what aspirin resistance means, the mechanism of aspirin resistance in 
diabetes including platelet activity, methods that are useful to identify aspirin resistance, 
and methods and management of aspirin resistance. 
2. Diabetes and cardiovascular risk 
Prevalence of diabetes is increasing rapidly worldwide. Diabetes is projected to affect 300 
million people around the world by 2025. Type 2 diabetes is the most common form of 
diabetes. The prevalence of type 2 diabetes increases with age.  Type 2 DM creates a 
prothrombotic state that is related to endothelial dysfunction, impaired fibrinolysis, 
increased levels of coagulation factors, and high platelet reactivity.(Carr 2001) Diabetes is 
considered as a coronary artery disease equivalent for future risk of vascular events 
http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf.  Despite a decline in 
mortality from CVD over the past decade, DM remains a key risk factor for CVD. 
Individuals with diabetes are at a 2- to 4-fold increased risk of cardiovascular events 
compared with age- and sex-matched individuals without diabetes. In diabetic patients over 
the age of 65 years, 68% of deaths are from coronary heart disease (CHD) and 16% are from 
stroke.(Pignone, Alberts et al. 2010) National Health and Nutrition Examination Survey data 
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suggest that declines in all-cause mortality have occurred among men with DM but not 
women. Mortality rates among individuals with DM remain approximately 2-fold higher 
compared to individuals without DM.(Preis, Hwang et al. 2009) Mechanisms leading to 
prothrombotic state are shown in the Figure 1.  
 
 
Fig. 1. Mechanisms leading to prothrombotic states in type 2 diabetes 
3. Aspirin 
Aspirin is one of the most important therapeutic agents used in the prevention of CVD (both 
primary and secondary) in patients with diabetes. Long-term aspirin administration in 
patients at high risk of occlusive vascular events reduced up to 34% of nonfatal myocardial 
infarction (MI), 25% of nonfatal stroke, and 18% of all-cause mortality. Low-dose aspirin (as 
low as 81 mg/day) irreversibly inhibits the COX-1 enzyme, by acetylating the serine residue 
at position 529, consequently impairing the transformation of arachidonic acid to 
prostaglandin (G2/H2), and TX A2, which is a potent mediator of platelet aggregation and 
activation. Aspirin's effect on COX-2 is minimal in doses <1200 mg per day.(Bucchi, 
Bodzenta et al. 1986; Frolich 1997)    Equivalent doses of the enteric-coated aspirin are said to 
be as effective as plain aspirin.(Cox, Maree et al. 2006) Lower bioavailability of these 
preparations and poor absorption from the higher pH environment of the small intestine 
may result in inadequate platelet inhibition, particularly in heavier patients.(Cox, Maree et 
al. 2006)  
3.1 Aspirin as a primary prevention strategy in diabetes mellitus 
The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial 
(Ogawa, Nakayama et al. 2008) was the first prospectively designed trial to evaluate the use 
of aspirin (81 mg or 100 mg) in the primary prevention of cardiovascular events in patients 
www.intechopen.com
 
Diabetes and Aspirin Resistance 
 
93 
with type 2 diabetes (n = 2,539) aged 30–85 years in Japan, and reported that aspirin use was 
associated with a 32% reduction in the risk of the primary end point at 4.7 years of follow 
up. The ongoing trials that will provide insights into the appropriateness of aspirin usage in 
diabetic patients include the Aspirin and Simvastatin Combination for Cardiovascular 
Events Prevention Trial in Diabetes (ACCEPT-D).(De Berardis, Sacco et al. 2007) Results of 
the Prevention Of Progression of Arterial Disease And Diabetes (POPADAD) trial have been 
reported, with no benefit with aspirin or antioxidants in primary prevention of 
cardiovascular events.(Belch, MacCuish et al. 2008) ADA recommends enteric-coated aspirin 
at a dosage of 81–325 mg to be used as a preventive strategy in high-risk diabetic 
individuals.(Pignone, Alberts et al. 2010) An important consideration is that patients may 
acquire additional risk factors over time, which would necessitate a reassessment of their 
overall risk profile. Several meta-analyses have explored the benefit of aspirin therapy in the 
primary prevention of major adverse cardiovascular events (MACE) among patients with 
diabetes.(Baigent, Blackwell et al. 2009; Calvin, Aggarwal et al. 2009; De Berardis, Sacco et al. 
2009; Pignone, Alberts et al. 2010; Younis, Williams et al. 2010; Zhang, Sun et al. 2010)  There 
are several tools to calculate the risk.  Tools that can be used in patients with diabetes are 
available from several sources, for example: UKPDS Risk Engine: 
http://www.dtu.ox.ac.uk/riskengine/index.php; ARIC CHD Risk Calculator: 
http://www.aricnews.net/riskcalc/html/RC1.html; American Diabetes Association Risk 
Assessment Tool, Diabetes PHD: http://www.diabetes.org/phd.   The AHA has issued 
similar guidelines and recommends 75–160 mg/day of aspirin as a primary prevention 
strategy in high-risk individuals, defined as those with a 10-year risk of coronary artery 
disease (CAD) over 10%. 
3.2 Aspirin as a secondary prevention strategy in diabetes mellitus 
Two large meta-analyses of major secondary prevention trials by the Antithrombotic 
Trialists' Collaboration (ATC) showed oral aspirin to be protective in patients at high risk for 
CVD, including those with diabetes (1994; 2002). The meta-analyses included 287 secondary 
prevention trials involving 212,000 high-risk patients with acute or prior vascular disease or 
another condition that increased their risk of vascular disease. Of note, a low dose of aspirin 
(75–150 mg/day) was found to be at least as effective as higher daily doses. In more than 
4,500 diabetic patients studied in the ATC, the incidence of vascular events was also reduced 
from 23.5% in the control group to 19.3% in the group treated with antiplatelet therapy (P < 
0.01) and from 17.2% to 13.7% in the ~42,000 nondiabetic patients (P < 0.00001). The ADA 
recommends the use of aspirin (81–325 mg/day) as a secondary prevention measure in 
diabetic patients with atherosclerotic disease. (Pignone, Alberts et al. 2010) 
3.3 Aspirin resistance 
Aspirin resistance, defined as failure of suppression of thromboxane generation, increases 
the risk of cardiovascular events in a high-risk population.(Eikelboom, Hirsh et al. 2002) 
Causes of aspirin resistance include concurrent use of nonsteroidal anti-inflammatory drugs 
such as ibuprofen that may compete with aspirin at the COX-1 receptor site,(Catella-
Lawson, Reilly et al. 2001) polymorphisms in the COX-1 gene,(Eikelboom, Hirsh et al. 2002; 
Halushka and Halushka 2002) poor glucose control, body weight, and conditions associated 
with a high platelet turnover.(Zimmermann, Wenk et al. 2003; Zimmermann, Kurt et al. 
2005; Guthikonda, Lev et al. 2007; Modica, Karlsson et al. 2007)  
www.intechopen.com
Recent Advances in the Pathogenesis, Prevention and  
Management of Type 2 Diabetes and its Complications 
 
94
3.4 Terminology (Ben-Dor, Kleiman et al. 2009) 
The lack of agreement on a standardized definition for “aspirin resistance” has contributed 
to the disparity in reports of its incidence among different studies. Whereas some use the 
term “aspirin treatment failure,” others like to call it “aspirin non responsiveness.” The term 
aspirin resistance has been used to describe the occurrence of cardiovascular events despite 
regular aspirin intake at recommended doses. 
3.5 Diabetes and aspirin resistance 
The benefit of aspirin in diabetic patients has been consistently documented in several 
trials. Aspirin is recommended for primary and secondary prevention in DM. Yet, in the 
meta-analysis of the ATC, the event rate of DM patients on treatment was similar to that 
of non-DM patients off treatment.(2002) In the Primary Prevention Project Trial, aspirin 
treatment reduced cardiovascular events and deaths in high-risk non-diabetic patients, 
but not in patients with type 2 DM (T2DM). Furthermore, in the recent Japanese Primary 
Prevention of Atherosclerosis with Aspirin for Diabetes Study,(Ogawa, Nakayama et al. 
2008) a low dose of aspirin in primary prevention did not reduce the risk of 
cardiovascular events at 4 years in diabetic patients. Other studies in secondary 
prevention similarly suggested that aspirin might be less effective in T2DM, especially in 
patients with poor metabolic control, than in non-DM patients, the underlying mechanism 
being still debated. Since platelets play a key role in the development of atherothrombotic 
events, the dysfunctional status of platelets in DM patients may contribute to the 
enhanced atherothrombotic risk of these patients.  It has been proposed that reduced 
sensitivity to aspirin in diabetic patients might be owing to accelerated 
thrombopoiesis,(DiMinno, Silver et al. 1986) or to reduced platelet permeability to aspirin 
caused by membrane glycosylation.(Winocour, Watala et al. 1992)  
The mechanisms that lead to increased platelet reactivity observed in patients with DM 
can be grouped together into the following aetiopathogenic categories: a) hyperglycaemia, 
b) insulin deficiency and resistance, c) associated metabolic conditions, and d) other 
cellular abnormalities (as shown in Figure 2). Poor glucose control and body weight are 
also proposed to contribute to aspirin resistance. (Watala, Golanski et al. 2004; Singla, 
Antonino et al. 2009) Poorly controlled patients with diabetes have the greatest platelet 
reactivity. High platelet reactivity was defined as >46% for 5 micromol/L ADP-induced 
and >59% for 20 micromol/L ADP-induced platelet activity and may require alternative 
antiplatelet strategies, and further clinical investigations are warranted.(Singla, Antonino 
et al. 2009)  
Platelets: Platelets play a key role in the development of atherothrombotic events. Platelets 
are essential for primary hemostasis and repair of the endothelium, but they also play a key 
role in the development of acute coronary syndromes and contribute to cerebrovascular 
events. Platelet adhesion is an essential function in response to vascular injury and is 
generally viewed as the first step during which single platelets bind through specific 
membrane receptors to cellular and extracellular matrix constituents of the vessel wall and 
tissues. Beyond acute activation as a consequence of vascular injury, circulating platelets are 
actively involved in all phases of the atherogenetic process, from atherosclerotic plaque 
formation to plaque inflammation and rupture. (Davi and Patrono 2007; Ruggeri and 
Mendolicchio 2007; Langer and Gawaz 2008)  
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Fig. 2. Mechanisms that lead to Platelet dysfunction in diabetes 
Mechanism of aspirin resistance in diabetes: Increased platelet reactivity observed in 
patients with DM may be secondary to several factors. Acute hyperglycemia as well as poor 
control of diabetes is associated with increased platelet reactivity. Comparative studies of 
patients with good glycemic control show they have better response to aspirin compared to 
the patients with poor glycemic control. Although this might implicate that better glucose 
control leads to less incidence of aspirin non-responsiveness, the clinical significance of such 
findings should be carefully inspected, since in 2 of the largest trials assessing the role of 
aspirin on primary prevention of cardiovascular events in patients with type 2 diabetes, 
low-dose aspirin did not decrease the risk of cardiovascular events when compared to 
placebo. Insulin resistance, TNF-alfa and IL-6 are shown to affect platelet reactivity. The 
clinical determinants that help identify aspirin resistance in diabetes are suggested to be 
CVD, microalbuminuria, poor diabetes control, and increased waist circumference.(Yassine, 
Davis-Gorman et al. 2010)  
Platelet abnormalities in Type 2 diabetes: The  abnormalities described in patients with 
diabetes are listed here. 
1. Increased production of thromboxane A2 from arachidonic acid. (Halushka, Mayfield et 
al. 1981; Halushka, Rogers et al. 1981) 
2. Increase in platelet-dependent thrombin generation. 
3. Increased expression of platelet surface adhesion molecules such as CD31, CD49b, 
CD62P, and CD63, leading to increased platelet activation.  
4. Increased platelet surface receptors such as P-selectin, GP Ib, and GP IIb/IIIa. (Gresele, 
Guglielmini et al. 2003) 
5. Reduced vascular synthesis of the anti-aggregants PGI2 and NO, shifting balance 
towards aggregation and vasoconstriction. 
6. Disordered calcium homeostasis that affects platelet shape change, secretion, aggregation, 
and thromboxane formation (Halushka, Mayfield et al. 1981; Halushka, Rogers et al. 
1981). 
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7. Decreased platelet insulin receptor number and affinity and failure to reduce platelet 
responses to the agonists ADP, collagen, thrombin, arachidonate, and PAF. 
8. Glycation of circulating LDL rendering platelets hypersensitive. Glycated LDL causes 
an increase in intracellular calcium concentration and platelet NO production, as well 
as inhibition of the platelet membrane Na+/K+-ATPase activity. 
Key: GP = glycoprotein; PGI2 = prostacyclin; NO = nitric oxide; ADP = adenosine 
diphosphate; PAF = platelet-activating factor; LDL= low-density lipoprotein; Na+/K+-
ATPase = Na+/K+-adenosine triphosphatase 
An accelerated platelet turnover represented by the presence of a higher number of 
reticulated platelets has been observed in patients with DM.(Guthikonda, Alviar et al. 2008)  
The dysfunctional status of platelets in patients with DM may contribute to the enhanced 
atherothrombotic risk of these patients.  Platelets obtained from diabetic patients show 
increased adhesiveness, hyperfunction both spontaneous as well as in response to agonists. 
These observed hyperfunctions are attributed to increased expression, activation or 
abundance of surface membrane receptors for agonists as well as cell matrix components, 
increased binding of fibrinogen, altered membrane fluidity, changes in activation 
mechanisms and signaling pathways. Changes in platelets in diabetes include enhanced GP 
receptor binding of agonists and adhesive proteins; decreased membrane fluidity; enhanced 
activation of the arachidonic acid pathway resulting in increased TxA2 formation; altered PI 
turnover leading to changes in diacylglycerol and inositol triphosphate production, calcium 
mobilization, and protein phosphorylation; impaired responses to antiaggregants resulting 
in decreased PGI2 receptor binding, cyclic nucleotide production and cyclic nucleotide–
dependent protein phosphorylation; and reduced sensitivity to the inhibitory actions of 
insulin. These changes translate to impaired PGI2 stimulation of cAMP and blindness to the 
inhibitory actions of both PGI2 and NO. Platelet dysfunction coupled with decreased 
endothelial production of these antiaggregatory agents conspire to amplify the risk of CVD 
in patients with type 2 diabetes.(Vinik, Erbas et al. 2001)  
Metabolic control and platelet reactivity 
In the early 1960s Bridges et al showed that both in vitro as well as in vivo administration of 
glucose increased platelet stickiness.(Bridges, Dalby et al. 1965) Combined hyperinsulinemia 
and hyperglycemia in healthy volunteers increased circulating tissue factor, plasma 
thrombin generation, and coagulation factors VII and VIII activities, suggesting that the 
coagulation system had been activated.(Boden and Rao 2007) Chronic hyperglycemia has 
been identified as a causal factor for in vivo platelet activation and platelet hyperreactivity in 
DM patients as evidenced by enhanced TXA2 biosynthesis.(Davi, Gresele et al. 1997; Davi, 
Ciabattoni et al. 1999) Of note, T2DM platelets are characterized by enhanced thromboxane 
biosynthesis and tight metabolic control, shown to lead to a reduction of thromboxane 
levels.(Davi, Catalano et al. 1990) Acute, short-term hyperglycemia induces an increased 
activation of platelets exposed to high shear stress conditions in vitro (filtration method) or 
in vivo (bleeding time). In vivo platelet activation is reflected by an increased urinary 
excretion of 11-dehydro-TxB (2).(Gresele, Guglielmini et al. 2003) This acute hyperglycemia-
induced enhancement of platelet activation is resistant to aspirin: an NO -donating agent 
suppresses it.(Gresele, Marzotti et al. 2010) LDL, a circulating complex of lipids and proteins 
that is increased in hypercholesterolemia, enhances platelet function and sensitizes platelets 
via binding of apoB-100 to a receptor on the platelet membrane and via transfer of lipids to 
the platelet membrane.(Relou, Hackeng et al. 2003) Hyperglycemia also induces an increase 
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in nonenzymatic glycation of LDL (glycLDL), which renders them more susceptible to 
oxidative stress.(Angiolillo 2007)  
Insulin and platelet reactivity 
The T2DM patients had platelet aggregation and shear-induced platelet function 
significantly increased compared to nondiabetic patients using all assays. Platelet 
aggregation was increased in ITDM (n = 68) compared with NITDM (n = 133) patients after 
P2Y12-specific stimuli. Insulin treatment was the strongest predictor of ADP-induced 
aggregation. Platelet function profiles were similar between ITDM and NITDM using assays 
non-specific to the P2Y12 pathway. Platelet dysfunction was independent of glycemic 
control and inflammatory status.(Angiolillo, Bernardo et al. 2006)  
NF-kB is a transcription factor that stimulates numerous genes and activates inflammatory 
responses related to insulin resistance. Salicylates inhibit NFkB activation. This inhibition 
was shown to be associated with a significant decrease in IL-6 and TNF-┙ release, mediated 
through inhibition of IKK┚ activity.  
Platelet activity measures 
A major urinary metabolite of thromboxane A2 synthesized from extra renal sources is 11-
dehydro thromboxane B2. A major portion of this metabolite is believed to come from the 
platelet, but there are additional cellular sources. In the Heart Outcomes Prevention 
Evaluation (HOPE) trial, patients whose urinary 11-dehydro thromboxane B2 levels were in 
the highest quartile had an odds ratio of 2 for having a myocardial infarction and an odds 
ratio of 3.5 for a risk of having a cardiovascular-related death compared to those patients in 
the lowest quartile. Serum aspirin esterase (AE) activity may account for part of aspirin 
pharmacokinetics and has been proposed as one source of variation in aspirin 
effectiveness.(Adebayo, Williams et al. 2007) Elevated MPV values are associated with a 
shortened bleeding time and increased thromboxane B2 plasma levels. Thus, MPV could be 
considered an indicator of platelet function.(Vizioli, Muscari et al. 2009) Diabetic patients 
with coronary heart disease have significantly higher MPV values compared to control 
patients.(Tavil, Sen et al. 2010)  
Methods that directly measure the capacity of platelets to synthesize TxA2 are certainly 
preferable. Of these, the urinary levels of the TxB2 metabolite, 11-dehydrothromboxane B2, 
represent a time-integrated index of TxA2 biosynthesis in vivo.(Patrono, Ciabattoni et al. 
1986) 11-dehydro-TxB2 is the most abundant urinary metabolite of TxB2.  Detection in the 
urine of this metabolite, which is not formed in the kidney, reflects systemic TxA2 formation, 
which largely, albeit not exclusively, occurs in the platelets. It has been calculated that about 
30% of the urinary metabolite derives from extra-platelet sources, as in inflammatory 
diseases, the contribution of extra-platelet sources may increase in atherosclerosis and 
inflammatory conditions.(Catella and FitzGerald 1987) Test measures consider the end 
products of the TxA2pathway such as serum TxB2, or urine 11-dehydro-TxB2, for assessing 
aspirin activity.(Eikelboom, Hirsh et al. 2002) In fact, these 2 tests may better reflect the 
amount of TxA2 derived from sources other than platelets such as macrophages and 
monocytes, and on the COX-2 linked pathway of arachidonic acid, which is blocked by 
aspirin at very high doses (1200 mg/ day) only.(Bucchi, Bodzenta et al. 1986) Urinary 11-
dehydro- TxB2 concentration is affected by renal production of this substance. However, 
measurement of this metabolite is still commonly used in trials assessing aspirin resistance, 
due to its low cost and ease of measurement.(Eikelboom, Hirsh et al. 2002)  
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In aspirin-treated patients, elevated urinary 11-dehydro thromboxane B2 levels identify 
patients who are relatively resistant to aspirin and who may benefit from additional 
antiplatelet therapies or treatments that more effectively block in vivo thromboxane 
production or activity.(Eikelboom, Hirsh et al. 2002)  
Clinical implications 
The clinical implication of aspirin resistance as measured in vitro by the inability of aspirin 
to reduce platelet activation and aggregation by failure to suppress the platelet production 
of TXA has not yet been elucidated via prospective trials that have controlled for 
confounders, such as hypertension, and dyslipidemia. Large meta-analyses have found low-
dose aspirin to be as effective as high-dose aspirin in preventing vascular events, making a 
dose-dependent improvement in laboratory response clinically irrelevant. Causes of aspirin 
resistance include poor compliance, inadequate dose, drug interactions, genetic 
polymorphisms of cyclooxygenase-1, increased platelet turnover, and upregulation of 
nonplatelet pathways of thromboxane production. At present, there is no standardized 
approach to the diagnosis and no proven effective treatment for aspirin resistance. Further 
research exploring the mechanisms of aspirin resistance is needed in order to better define 
aspirin resistance, as well as to develop a standardized laboratory test that is specific and 
reliable, and can correlate with the clinical risk of vascular events.  
Management 
Factors that need to be considered in the approach to patients with suspected treatment 
failure include: compliance with aspirin use, ensure the optimal dose and drug form (avoid 
use of enteric-coated aspirin formulations), evaluate concomitant infections or inflammatory 
conditions, and assess possible drug–drug interactions. Several approaches have been 
evaluated for treatment failure and some of these approaches are based on laboratory 
testing for evidence of resistance. The role of testing in directing management is still 
controversial. Management strategies are currently limited to dosing alteration and 
introduction of other anti platelet agents. However, these measures have not met the 
expected efficacy or safety.  
Increased aspirin doses: The idea of increasing aspirin dose has been assayed in many studies, 
as there is some evidence that response to aspirin may be dose dependent.(ten Berg, 
Gerritsen et al. 2002) Because patients with diabetes exhibit a higher prevalence of aspirin 
resistance on standard aspirin doses (81 mg/day) and have significantly higher ADP- and 
collagen-induced platelet aggregation, 11-dehydro- TxB2 levels and the aspirin resistance 
may be partially overcome by higher aspirin doses.(DiChiara, Bliden et al. 2007) Laboratory 
and genetic inconsistency, as well as dose dependence, is seen when agonists other than 
arachidonic acid (the most specific in assessing aspirin resistance), such as ADP, collagen, 
and epinephrine, are used for in vitro assessment of platelet inhibition by aspirin.(McCabe, 
Harrison et al. 2005; Assadian, Lax et al. 2007; Gurbel, Bliden et al. 2007). The Clopidogrel vs 
Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial compared the efficacy for 
secondary prevention of clopidogrel (75 mg daily) versus aspirin (325 mg daily) in a high-
risk population (n = 19,185) consisting of patients with a history of recent MI, recent 
ischaemic stroke, or established peripheral artery disease.(Diener, Bogousslavsky et al. 2004) 
The benefit of clopidogrel therapy was higher (15.6% vs. 17.7%; P = 0.042) in DM patients, 
despite the increased incidence of ischaemic outcomes in this subgroup. The absolute 
reduction in events was highest among diabetic patients requiring insulin therapy.(Diener, 
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Bogousslavsky et al. 2004) In large, well-designed multicentre trials, such as CURE, 
COMMIT, and CLARITY-TIMI 28, the addition of clopidogrel to aspirin therapy improved 
outcomes in patients with acute coronary syndromes.(Plosker and Lyseng-Williamson 2007)   
Addition of other antiplatelet agents: Dual antiplatelet therapy using acetylsalicylic acid and 
clopidogrel is of great importance following coronary stenting. Clopidogrel, a 
thienopyridine, works by irreversibly inhibiting ADP binding to the P2Y12 receptors on the 
platelet surface, and ultimately interfering with platelet-fibrinogen binding. The PLATO 
(PLATelet Inhibition and Patient Outcomes) study has shown that ticagrelor, an agent with 
a similar mechanism of action to clopidogrel and still in phase III trials, showed a significant 
reduction of a combined endpoint of cardiovascular death, myocardial infarction, or stroke 
as compared with clopidogrel (hazard ratio 0.84; 95%CI 0.75, 0.94; P = 0.0025).(Cannon, 
Harrington et al. 2010) In the subgroup of patients undergoing coronary artery bypass graft 
(CABG) within 7 days after the last study drug intake, ticagrelor compared with clopidogrel 
was associated with a substantial reduction in total and cardiovascular mortality without 
excess risk of CABG-related bleeding.(Held, Asenblad et al. 2011) Addition of dipyridamole 
to aspirin can lead to significant platelet inhibition in aspirin-resistant patients. The addition 
of dipyridamole to aspirin appears to be more effective than aspirin alone in the prevention 
of secondary vascular events in stroke patients and does not cause an increase in 
haemorrhagic events compared to aspirin alone in an identical dose.(Diener, Darius et al. 
2001; Diener, Darius et al. 2001) There is also a suggestion that dipyridamole may partially 
compensate for aspirin resistance in patients with ischaemic stroke via an alternative 
antithrombotic mechanism.(Serebruany, Malinin et al. 2005; Serebruany, Malinin et al. 2006) 
In a study to determine whether treatment with dipyridamole or clopidogrel, in addition to 
aspirin, is more effective at reducing embolization and transient ischemic attacks, King and 
associates have shown that both dipyridamole and clopidogrel reduced embolization to a 
similar extent.(King, Bath et al. 2011) Other antiplatelet agents that may be more potent via 
alternative pathways are under investigation.  
Statins to improve aspirin resistance:  There is evidence that statins may be useful in treating 
aspirin resistance. Tirnaksiz and associates reported that in a study of patients with stable 
coronary artery disease, 11.2% were found to be aspirin resistant as measured by PFA-100, 
with a closure time of <186 seconds with collagen/adrenaline cartridges.(Tirnaksiz, 
Pamukcu et al. 2009) After 3 months of statin therapy (atorvastatin 10 mg/day), 65% of the 
aspirin-resistant patients became aspirin sensitive by PFA-100 measurements (P < 
0.0001).(Tirnaksiz, Pamukcu et al. 2009) Tekten and his colleagues have shown that statins 
reduced platelet aggregation.(Tekten, Ceyhan et al. 2004)  
Another recommendation is that because saturated fat ingestion increases in vivo 
thromboxane production despite aspirin therapy, diabetic patients on ASA therapy should 
have low dietary saturated fat intake and aggressive lipid management.(Yassine, Davis-
Gorman et al. 2010)  
4. Conclusion 
Aspirin is recommended for primary prevention and secondary prevention of CVD in 
patients with type 2 diabetes. Aspirin resistance is common in patients with type 2 diabetes. 
Further studies are required to answer the question, will improving glycemic control in 
patients with poor glycemic control  cause a change in responsiveness to aspirin? The 
relationship of the adipokines TNF-alfa and IL-6 to aspirin non-responsiveness needs 
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further evaluation. Prospective randomized trials are needed to prove the clinical benefits of 
adapting the dosing of clopidogrel or switching to alternative compounds in high-risk 
patients with impaired antiplatelet effectiveness according to the result of platelet function 
assays. 
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